Lumen Bioscience a Seattle-based clinical-stage biotechnology company, announced on Thursday that it has received a new USD8.8m project funded by the US Department of Defense (DOD) for the development and testing of a prototype broad-spectrum, fast-acting intranasal powder for treatment and prevention of known and emerging viral respiratory infections.
The contract was awarded by the Defense Innovation Unit (DIU) under its 'Project Panacea' and the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense's (JPEO-CBRND) Joint Project Manager for Chemical, Biological, Radiological, and Nuclear Medical (JPM CBRN Medical), under its Vaccine Acceleration by Modular Progression program.
The funding will support development and testing of intranasal host-directed therapeutic using Lumen's low-cost, highly scalable cGMP production platform and novel formulation technology. The therapeutic is a human immune signalling protein known to be especially important in the body's immune response to respiratory viral infections like influenza. Human clinical trials by other groups have shown that the therapeutic, when injected, was safe and effective against COVID-19 and other diseases. Animal experiments by other researchers show that intranasal dosing may be a safe and effective approach for both treating and preventing influenza and COVID-19. The new Lumen project unites these two lines of research, as well as testing other CBRN threats of interest. The project is intended to yield a prototype shelf-stable, inexpensive, self-administered product candidate ready for human trials.
Replicate Bioscience begins phase one trial of RBI-4000 vaccine
Moderna and Immatics form strategic collaboration to develop new oncology therapies
Pfizer and BioNTech's Omicron XBB.1.5-adapted COVID-19 vaccine receives positive CHMP opinion in EU
Valneva's chikungunya vaccine moves forward with Health Canada's review
Allucent Awarded BARDA Contract to Support Acceleration of Next-Generation COVID-19 Booster Vaccines
Anixa Biosciences advances ovarian cancer CAR-T trial with third patient
GC Biopharma signs MoU with GC Biopharma for co-production of Euvichol
GC Biopharma partners with Eubiologics for joint cholera vaccine production
GSK's Shingrix shows 100% efficacy against shingles in Chinese adults
Pfizer's Abrysvo receives FDA approval for pregnant individuals to prevent RSV in infants
Arcturus' mRNA manufacturing partner ARCALIS receives USD115m in grants from the Japanese government
Roquefort Therapeutics boosts patent portfolio with PCT Filing